Newsletter | January 23, 2024

01.23.24 -- 5 Leadership Learnings In Preventative Cancer Vaccine Development


5 Leadership Learnings In Preventative Cancer Vaccine Development

Calviri has been developing an RNA vaccine to prevent cancer for more than 20 years and repeatedly faced the nearly universal belief that it’s impossible. We’ve learned a number of important lessons along the way that are worth imparting to other vaccine developers.


Challenges Associated With In-Use Simulated Administration Of Biologics

Explore some of the more challenging aspects surrounding in-use testing for parenteral delivery along with potential strategies to address these issues.

Overcoming Limitations To Achieve Uniform Dosing

The formulation for low-dose drugs must ensure that each dosage has an acceptable blend and content uniformity. Choosing the right methods requires expertise across multiple areas of development.

Increasing Bioavailability With Amorphous Solid Dosage Formulations

Discover the challenges associated with pH-dependent solubility for oral TKI drugs and how leveraging ASD formulation can help create more effective, patient-friendly drug products.

Low-Volume Production For Screening High-Value Nanoparticle Materials

A platform that harnesses microfluidic mixing has been demonstrated as a simple, robust, and scalable production method for LNPs encapsulating various types of nucleic acids.



Debiopharm & Forge A Strategic Partnership

Neuraptive Therapeutics Inc. Receives ODD For Its Lead Development Asset

Cancer Drug Discovery Accelerated As Hundreds Of Overlooked Targets Prioritised

Molecular ‘Super-Glue’ Shows Promise Of Cancer Drug Discovery Platform

Washington University & Deerfield Management Launch VeritaScience

Accelerating How New Drugs Are Made With Machine Learning

SyntheticGestalt & Enamine To Collaborate On The Creation Of AI-Based Model

3D In Vitro Human Atherosclerosis Model For High-Throughput Drug Screening

ANI Pharmaceuticals Announces The FDA Approval Of Indomethacin OS, USP

Precigen Receives Orphan Drug Designation For PRGN-2012

Presage Announces FDA Study May Proceed To Test Pre-GMP Drug Candidate In CIVO


Selecting An Affinity Chromatography Resin For Your Antibody

High-Energy Chemistry